V. Bozoukova

Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccines.

Larry R. Smith, A. Rolland, M. Ye, 2009, Vaccine.

Sodium phosphate enhances plasmid DNA expression in vivo

K. Barnhart, L. Sukhu, M. Manthorpe, 2000, Gene Therapy.

Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization.

M. Ferrari, C. Wheeler, L. Sukhu, 2001, Vaccine.

Physical characterization and in vivo evaluation of poloxamer‐based DNA vaccine formulations

A. Nanci, A. Rolland, Ji-Hyun Yi, 2008, The journal of gene medicine.

Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens.

M. Ferrari, C. Wheeler, L. Sukhu, 2001, Vaccine.

Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus

Larry R. Smith, A. Rolland, S. Sullivan, 2012, Human vaccines & immunotherapeutics.

Comparison of Rabbit and Mouse Models for Persistence Analysis of Plasmid-Based Vaccines

D. Kaslow, A. Rolland, J. Hartikka, 2006, Human vaccines.

I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration.

D. Kaslow, A. Rolland, J. Hartikka, 2005, Human Gene Therapy.

II. Cationic lipid-formulated plasmid DNA-based Bacillus anthracis vaccine: evaluation of plasmid DNA persistence and integration potential.

D. Kaslow, A. Rolland, J. Hartikka, 2005, Human gene therapy.

Electroporation-facilitated delivery of plasmid DNA in skeletal muscle: plasmid dependence of muscle damage and effect of poloxamer 188.

C. Wheeler, L. Sukhu, J. Hartikka, 2001, Molecular therapy : the journal of the American Society of Gene Therapy.